Olink, part of Thermo Fisher Scientific: Plasma Proteomics: Driving a New Era for Cancer Research and Precision Medicine

Early cancer detection and the identification of reliable biomarkers for patient monitoring remain critical unmet needs in oncology. While many methods have struggled to deliver consistent or affordable solutions, proteomics can answer these challenges. In this session, Stefan Enroth, PhD, will present how analysing 5416 plasma proteins improved diagnostic accuracy in ovarian cancer, reducing the need for unnecessary biopsies by effectively identifying benign cases. Antoine Italiano, MD, PhD, will explore how plasma proteomics is advancing biomarker discovery and precision medicine in immuno-oncology, offering new insights into tumor-immune system interactions in clinical studies. Join us to discover how proteomics is revolutionizing cancer research and its clinical translation to shape the future of precision medicine.